The authors built a model for lung cancer diagnosis previously based on the blood biomarkers progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYFRA21-1). In the current study, they examined whether modification of the model to include relevant clinical information, risk factors, and low-dose chest computed tomography screening would improve the performance of the biomarker panel in large cohorts of Chinese adults. METHODS: The current study was a large-scale multicenter study (ClinicalTrials.gov identifier NCT01928836) performed in a Chinese population. A total of 715 participants were enrolled from 5 regional centers in Beijing, Henan, Nanjing, Shanghai, and Chongqing between October 2012 and February 2014. Serum biomarkers ProGRP, CEA, SCC, and CYFRA21-1 were analyzed on the ARCHI-TECT i2000SR. Relevant clinical information was collected and used to develop a patient risk model and a nodule risk model.
INTRODUCTION
Lung cancer has the highest incidence and mortality among all malignant tumors in China. 1 In 2015, it was estimated that there were 610,200 deaths from lung cancer (432,400 in males and 177,800 in females) in China. 2 Of the lung cancer deaths, approximately 87% are related to cigarette smoking. 3 The 10-year survival rate of patients with stage I disease is up to 88%. Therefore, early diagnosis of lung cancer is of key importance to ensure better outcomes of patients with lung cancer. 4 Unfortunately, approximately 88.2% of the patients with lung cancer in China are symptomatic when they present for treatment, and 65.3% are diagnosed with stage III or stage IV disease at presentation. 5 This further underscores the importance of the timely detection of early-stage lung cancer.
In the National Lung Screening Trial (NLST) (ClinicalTrials.gov identifier NCT00047385), low-dose computed tomography (LDCT) screening for lung cancer reduced lung cancer mortality by 20% compared with chest x-ray in a high-risk population (with a history of cigarette smoking of 30 pack-years and aged 55-74 years). 6 The NELSON (Dutch-Belgian Randomized Lung Cancer Screening) trial demonstrated that the lung cancers identified by screening were more often diagnosed at stage I and less often at stage IIIB to stage IV. 7 The final results regarding lung cancer mortality are pending in the NELSON trial. The DANTE (Detection And screening of early lung cancer with Novel imaging TEchnology) trial did not find a significant benefit for LDCT screening, 8 but the trial was smaller and perhaps underpowered. The potential benefit of screening is diminished by the false-positive results of CT scanning that lead to unnecessary and potentially harmful invasive procedures. 9 Currently, both the American College of Chest Physicians (ACCP) and Chinese Alliance Against Lung Cancer (CAALC) guidelines state that the procedure for lung nodule follow-up is mainly dependent on the nodule's diameter. [10] [11] [12] Several new serum biomarkers currently under investigation now are available to help detect early-stage lung cancer. 13, 14 Plasma DNA levels, for example, may improve the accuracy of CT screening for lung cancer. 15 The biomarker panels are more effective when combined with clinical parameters. 16 These findings prompted us to develop a multibiomarker predictive model for lung cancer risk assessment in Chinese patients and in nodules detected by CT. Our preliminary single-center study of a lung cancer biomarker panel found that 4 biomarkers in combination, including progastrin-releasing peptide (ProGRP), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and cytokeratin 19 fragment (CYRFRA21-1), can improve the efficacy of CT screening for lung cancer. 17 We evaluated this serum biomarker panel using realworld data in the first multicenter lung cancer biomarker panel (LCBP) study in a Chinese population, which was initiated by the Department of Respiratory Diseases at Shanghai Zhongshan Hospital Fudan University in October 2012. The current study included patients from 4 other hospitals, including Peking Union Medical College Hospital, Xinqiao Hospital (affiliated with the Third Military Medical University), Henan Provincial People's Hospital, and Nanjing People's Liberation Army General Hospital. Herein we report the training and validation of the proposed models and equations for predicting the probability of lung cancer in 1) high-risk Chinese patients and 2) those with nodules detected by CT. The objective of the current study was to build a local data set, which then could be used to validate the predictive accuracy of the LCBP. The results of the current study will help to establish the best practice and standardize the procedures in the early diagnosis of lung cancer in China.
MATERIALS AND METHODS

Overall Study Design
The current study was designed to evaluate a combination of 4 blood proteins (ProGRP, CEA, SCC, and CYRFRA21-1) and clinical information to predict the occurrence of cancer in patients at high risk of lung cancer. To this end, we developed 2 predictive models: one for all high-risk patients with or without nodules after CT scan (patient risk model) and the other for those patients with nodules detected by CT (nodule risk model) with the training data set. We subsequently validated these 2 models with the validation data set.
The training data set included the participants enrolled from Peking Union Medical College Hospital, Henan Provincial People's Hospital, and Nanjing People's Liberation Army General Hospital. The validation data set included the participants from Zhongshan Hospital and Xinqiao Hospital.
Blood samples were drawn from all patients. The serum was separated and stored immediately at -80 8C for later use. Clinical data (including age, sex, race, and past medical history), pathological diagnosis (including histology and stage of disease), and imaging findings (including CT data and nodule size) were entered into a secured trial database.
Patient Selection
All patients provided written informed consent before study entry. The informed consent form was approved by the Institutional Review Board of Zhongshan Hospital of Fudan University and the other 4 institutions in accordance with an assurance filed with and approved by the Department of Health and Human Services. This study was registered at ClinicalTrails.gov (ClinicalTrials.gov identifier NCT01928836).
A total of 389 patients at high risk of lung cancer were included in the training data set between December 2013 and February 2014 (Tables 1 and 2 ). Blood samples were collected from all patients. The inclusion criteria were: 1) aged 18 to 90 years; 2) male smoker (400 cigarettes/year), female smoker, or nonsmoker; 3) no history of lung cancer; and 4) no currently known extrathoracic malignancy. An additional inclusion criterion is required for the nodule model, namely chest CT revealing an indeterminate pulmonary nodule. The exclusion criteria included: 1) the absence of histopathological diagnosis and 2) prior chemotherapy or surgical treatment. A total of 326 patients at high risk of lung cancer were included in the validation data set between October 2012 and January 2014. The above inclusion and exclusion criteria also were applied to this data set (Tables 1 and 2 ). Laboratories). These markers were assayed using a commercial chemiluminescent microparticle immunoassay method on the ARCHITECT i2000SR platform, an automated immunoassay analyzer (Abbott Laboratories). All samples in the training set were run in duplicate. In the validation study, all assays were run on an automated analyzer as per the manufacturer's instructions.
Imaging Studies, Nodule Size, and Pathological Staging All the patients in either the training or validation arms underwent a chest CT study. The CT studies were performed using multiple contiguous sequential axial images through the thorax at all the 5 participating centers. The nodule size was analyzed with PneuView system (Myrian, Paris, France). The maximum dimension on axial CT images was recorded. Histological diagnosis was made according to the criteria of the 2004 World Health Organization classification of lung tumors, 18 and disease stage was determined following the TNM staging criteria in the seventh edition of American Joint Committee on Cancer staging manual. 19 A without lung cancer referred to the patient with an alternative histologic diagnosis, nodule resolution on CT image, documented 2-year stability of the nodule, or 2-year clinical observation without evidence of lung cancer.
Statistical Analysis
Continuous data were presented as the mean 6 the standard deviation (SD) and analyzed with the Student t test followed by analysis of variance, whereas categorical data were expressed as the number and percentage. Multivariable logistic regression was used to evaluate the risk of lung cancer associated with potential predictors based on the existing knowledge of risk factors for lung cancer, such as family history, clinical characteristics, and serum levels of the LCBP parameters (ProGRP, CEA, SCC, and CYFRA21-1).
Two predictive models (the patient risk model and nodule risk model) were developed based on statistical analysis and local clinical experience. The following variables were included in the patient risk model: age; sex; smoking status; history of cancer; and serum expression level of ProGRP, SCC, CYFRA21-1, and CEA. The variables included in the nodule risk model were age; sex; smoking status; diameter of nodules; spiculation feature; and serum expression level of ProGRP, SCC, CYFRA21-1, and CEA. The predictive models were developed with the training data set and evaluated for their predictive performance with the validation data set, including their discrimination (ability to classify correctly) and calibration (comparability between predicted and observed probabilities). The discrimination was measured with the area under the receiver operating characteristic (ROC) curve. The sensitivity, specificity, and accuracy were calculated for all models. The calibration was evaluated by subtracting the model-estimated probability from observed probability for each subject in this study. The patients were further stratified into the following risk strata based on the 10 The prediction model of the Mayo Clinic is described by the following equations: probability of malignancy 5 e x / (11 e x ), 3 5 -6.8272 1 (0.0391 3 age) 1 (0.7917 3 smoke) 1 (1.3388 3 cancer) 1 (0.1274 3 diameter) 1 (1.0407 3 spiculation) 1 (0.7838 3 location), in which "e" is the base of natural logarithm, age is the patient's age in years, smoking status e 5 1 if the patient is a current smoker or former smoker (otherwise 5 0), cancer 5 1 if the patient has a history of an extrathoracic cancer diagnosed >5 years previously (otherwise 5 0), diameter is the diameter of the nodule in millimeters, spiculation 5 1 if there are spicules at the edge of the nodule (otherwise 5 0), and location 5 1 if the nodule is located in upper lobe (otherwise 5 0). All P values are 2-sided. A P value < .05 indicates statistical significance. The statistical analysis was conducted with SPSS statistical software (version 20.0; IBM Corporation, Armonk, New York).
RESULTS
Study Population
In the patient risk model study, a total of 715 subjects with a high risk of lung cancer were enrolled, including 389 subjects in the training data set and 326 subjects in the validation data set. In the nodule risk model study, a total of 342 subjects with lung nodules were enrolled, including 163 subjects in the training data set and 179 subjects in the validation data set (Figure 1 ). The characteristics of the subjects in the training and validation data sets are presented in Table 1 and Table 2 , respectively.
Biomarker Level in the Total Population
Significantly higher levels of ProGRP (P<.001), SCC (P<.001), CYFRA21-1 (P<.001), and CEA (P 5 0.026) were observed in patients with lung cancer compared with the controls who had no indication for lung biopsy ( Fig. 2A) . Similar results were observed when the patients with lung cancer were compared with the patients with a normal biopsy (ProGRP: P<.001; SCC: P<.001; CYFRA21-1: P<.001; and CEA: P 5 0.310).
CEA levels did not demonstrate a significant difference between patients with lung cancer and the patients with a nonmalignant nodule. As expected, significantly higher level of ProGRP were observed in patients with small cell lung cancer compared with both adenocarcinoma (P<.001) and squamous cell carcinoma (P<.001). The SCC level was higher in patients with squamous cell cancer than in those with adenocarcinoma and small cell cancers (Fig. 2B) . Figure 2C presents the serum levels of the 4 biomarkers in the patients with lung cancer with smaller nodules (diameter < 20 mm) and those with larger lung nodules or lesions (diameter > 20 mm). Significantly higher levels of ProGRP (P 5 0.036) were observed in patients with larger malignant lesions compared with those with smaller malignant lesions. Similar results were obtained when the patients at advanced stage (stage IIIB-IV) were compared with the patients with limited stage (stage I-IIIA) disease (CEA: P<.01) (Fig. 2D ).
Patient Risk Model
We analyzed 389 subjects at high risk of lung cancer to develop the patient risk model without using the nodule information from the CT scan result. Logistic regression revealed that ProGRP, CEA, SCC, CYFRA21-1, age, smoking status, cancer history, and sex were significant variables with which to predict the diagnosis of lung cancer in the high-risk population (Table 3 ). In the validation study, we analyzed 326 high-risk participants to validate the proposed patient risk model.
We derived an equation from the logistic regression model to calculate the probability of cancer in the high-risk population (probability of malignancy5e cutoff values were determined in the training set and tested in the validation set.
The proposed patient risk model showed excellent discrimination in both the training and validation data sets, as evidenced by the area under the ROC curve of 0.7037 and 0.7190, respectively (Figs. 3A and 3B) . The sensitivity and specificity of this model were validated but varied according to different settings (Table 4) .
Nodule Risk Model
We analyzed a total of 163 subjects with nodules in the training data set. We developed the nodule risk model after introducing CT scan data. Logistic regression identified that ProGRP, CEA, SCC, CYFRA21-1, age, smoking status, nodule diameter, spiculation, and sex were significant variables with which to predict lung cancer in the population with lung nodules (Table 5 ). In the validation study, we analyzed 179 subjects with lung nodules to validate the proposed nodule risk model.
An equation was derived from the logistic regression model to calculate the probability of cancer (probability of malignancy 5 e . A calculated cancer probability of 0.94 (cutoff value of 1) or higher signifies the presence of lung cancer (high risk), and a probability of <0.22 (cutoff value of 2) predicts the absence of lung cancer (low risk).
In the training data set, the nodule risk model showed excellent discrimination with an AUC of 0.9151, but the discrimination was very limited in validation data set (AUC, 0.5836) (Figs. 4A and 4B ). Only CYFRA21-1 was found to be independently associated with the risk of lung cancer (P<.05) ( Table 5 ). The other biomarkers were not found to be significant predictors except for CEA. CEA levels were inversely correlated with lung cancer risk (Table 5 ).
In addition, we compared this nodule risk model with the ACCP model for the prediction of lung cancer in the 163 subjects with nodules in the training data set. In this population, the performance of our proposed nodule risk model was better than that of the ACCP model, as evidenced by its significantly smaller area under the ROC curve (0.9151 vs 0.8360; P 5 0.001) (Fig. 5) .
DISCUSSION
Lung cancer screening based on LDCT alone frequently identifies patients with indeterminate abnormalities. Further testing evaluation is required to confirm the diagnosis. Current guidelines recommend multiple sequential CT scans to detect the growth of a pulmonary nodule, or combined with positron emission tomography and invasive procedures depending on lung cancer risk stratification and size of the lesion. These testing requirements of LDCT screening place a significant burden on the health care system. Several studies have shown that the use of tumor-specific, noninvasive biomarkers can modify the paradigm and improve testing efficiency, but to the best of our knowledge the majority of these studies focused on white populations. Age is the patient's age in years; current smoking is 1 if the patient is a current smoker or former smoker (otherwise, it is 0); nodule diameter is the diameter of the nodule in millimeters; spiculation is 1 if there are spicules at the edge of the nodule (otherwise, it is 0); sex is 1 if the patient is male (otherwise it is 0); and ProGRP, SCC, CYFRA21-1, and CEA is the serum expression level of ProGRP, SCC, CYFRA21-1, and CEA in pg/mL, ng/mL, ng/mL, and ng/mL, respectively. With multidetector spiral CT and LDCT scans widely used to screen the subjects at high risk of lung cancer, the detection of solitary pulmonary nodules has significantly increased, ranging from approximately 8% to 51%. 20 To examine the nature of such nodules, we studied 715 subjects at high risk of lung cancer, including 294 patients with malignant tumors. Two models were developed and validated for the early diagnosis of lung cancer based on clinical information and serum protein biomarkers. The 2 proposed models specifically target at-risk patients and lung nodules, respectively. Both models demonstrated good performance, as evidenced by the area under the ROC curves and by the relatively high sensitivity and specificity. Specifically, our nodule risk model provided better accuracy in patient stratification (accuracy of 82.2% vs 62.6% and an AUC of 0.9151 vs 0.8360; P<.01) compared with the ACCP model in our population with lung nodules.
Smaller solitary pulmonary nodules (diameter < 1 cm) currently are detected much more frequently. However, only 1.1% to 12.0% of these solitary nodules are found to be malignant. 21 These malignant tumors are difficult to differentiate from the benign ones due to the limitations of current diagnostic methods, 22 especially for solitary pulmonary nodules measuring <8 mm in diameter. The proposed nodule risk model can be used to evaluate the risk of lung cancer before surgery in patients with or without pulmonary nodules. The data from our study in a high-risk Chinese population have shown that the sensitivity and specificity of this model are nearly 90% in the identification of lung cancer. Identifying malignant nodules at an early stage is favorable for selecting more appropriate treatment strategies to achieve optimal treatment efficacy. Such a screening tool may prove to be useful for physicians in both specialty and general settings, especially the physicians working in community centers and remote areas.
The current study is an extension of our previous single-center study on a serum marker panel intended for the early diagnosis of lung cancer in China. In this prospective, case-control, multicenter study, we combined these markers with the most predictive imaging features of lung cancer and nodule size to classify the enrolled Chinese patients with indeterminate nodules into low-risk and high-risk strata. Subsequently, we developed and validated the patient risk model targeting individuals living in rural area of China, who have limited access to LDCT testing. Once validated, local physicians will be able to routinely take advantage of this model based on clinical features and blood biomarkers to estimate the risk of lung cancer appropriately. Based on risk stratification, highrisk patients would be referred to oncologists for further evaluation. Our nodule risk model in addition takes into account the CT scan result. This upgraded model demonstrates better accuracy on risk predication than the ACCP lung nodule model. The results of the nodule risk model, once validated, can be used to routinely assign high-risk patients to receive more immediate intervention with biopsy, positron emission tomography, or close surveillance. The patients assigned to the low-risk category can be followed with less frequent CT scans. Therefore, this model can be used to evaluate a patient with lung nodule preliminarily, which may avoid unnecessary invasive procedures such as biopsy or surgery.
Many factors contribute to the delay of diagnosis of lung cancer, such as failure to recognize abnormal imaging results, failure to perform key diagnostic procedures within a short period, and misinterpretation of pathology reports. 23, 24 Currently in China, the procedures for the early diagnosis of lung cancer are primarily localized in general hospitals. To improve the efficiency and efficacy of lung cancer diagnosis in China, there are 2 ongoing prospective clinical lung cancer screening trials based on serum biomarker panels: the Early Cancer Detection Test-Lung Cancer Scotland (ECLS Study) 25 and the blood-based lung cancer biomarkers screening study. 21 Our previous preliminary single-center study demonstrated that a panel of 4 biomarkers can improve the efficacy of CT scanning in identifying patients with lung cancer. 17 To the best of our knowledge the current study is the first multicenter LCBP study conducted in a Chinese population. We evaluated the performance of the proposed serum biomarker panel with real-world data. The results support this panel test as a useful aide that may help clinicians to estimate the risk of lung cancer comprehensively and scientifically.
There are several limitations to the current study. First, although the nodule risk model demonstrated excellent discrimination in the training data set, its discrimination was more limited in the validation data set, which is potentially attributable to overfitting of the model. However, the model was validated in patients in other settings such as in patients with lung diseases without nodules and in healthy subjects. The additional validation cohorts provide additional evidence in support of the test's clinical usefulness. Additional studies are planned to determine the impact of integrating serum biomarker results with nodule size within existing screening programs. Currently, we have launched a large-scale lung cancer screening study based on these 2 models, which is expected to improve early diagnosis and decrease the mortality of lung cancer in China. These studies will be helpful for defining the frequency and use of sequential follow-up imaging or repeat serum marker tests. Ultimately, we expect that integration of blood biomarker testing with CT imaging results will be an efficient and effective approach that will improve the early and accurate diagnosis and outcomes of high-risk patients with indeterminate pulmonary nodules.
